Abstract | STUDY OBJECTIVES: DESIGN: Retrospective case-control study. DATA SOURCE: Oregon Medicaid claims database. PATIENTS: A total of 288 case patients and 1652 control patients. MEASUREMENTS AND MAIN RESULTS: Case patients were defined as any patients hospitalized for heart failure, controls as any patients with a hospital claim for a condition other than heart failure. Controls were matched by age and sex in a 6:1 ratio. Exposure to a thiazolidinedione or other antihyperglycemic drug was assessed 60 days before the first hospitalization. This was used to construct an odds ratio of exposure in case patients compared with controls using a multivariate logistic regression model and controlling for potential confounders. Charlson comorbidity index scores and frequency of diabetes-related office visits were significantly higher for case patients than for controls. The unadjusted and adjusted odds ratios for exposure to a thiazolidinedione were 1.71 (95% confidence interval [CI] 1.24-2.36) and 1.37 (95% CI 0.98-1.92), respectively. The unadjusted and adjusted odds ratios for exposure to insulin in patients hospitalized for heart failure were 1.68 (95% CI 1.27-2.22) and 1.25 (95% CI 0.92-1.69), respectively. The unadjusted and adjusted odds ratios for exposure to a combination of insulin and a thiazolidinedione in case patients were 1.81 (95% CI 1.14-2.86) and 1.35 (95% CI 0.84-2.18), respectively. No association with hospitalization for heart failure was found for patients exposed to a sulfonylurea, metformin, or alpha-glucosidase inhibitor. CONCLUSION:
|
Authors | Daniel M Hartung, Daniel R Touchette, Nanette C Bultemeier, Dean G Haxby |
Journal | Pharmacotherapy
(Pharmacotherapy)
Vol. 25
Issue 10
Pg. 1329-36
(Oct 2005)
ISSN: 0277-0008 [Print] United States |
PMID | 16185176
(Publication Type: Journal Article)
|
Chemical References |
- Chromans
- Hypoglycemic Agents
- Thiazolidinediones
- Rosiglitazone
- Troglitazone
- Pioglitazone
|
Topics |
- Adult
- Aged
- Case-Control Studies
- Chromans
(adverse effects)
- Diabetes Mellitus, Type 2
(drug therapy)
- Female
- Heart Failure
(chemically induced)
- Hospitalization
- Humans
- Hypoglycemic Agents
(adverse effects)
- Male
- Medicaid
- Middle Aged
- Pioglitazone
- Retrospective Studies
- Risk
- Rosiglitazone
- Thiazolidinediones
(adverse effects)
- Troglitazone
|